Abstract
ANP gene therapy in nephrotoxicity 1377 in accordance with National Institutes of Health Guide for to cause blood pressure reduction in animals and the Care and Use of Laboratory Animals.
hypertensive human subjects in either short or long term infusion [9] . Infusion of ANP was found to be Reverse transcription-polymerase chain reaction effective in primary aldosteronism, glomerulonephritis, (RT-PCR) and Southern blot analysis of ANP mRNA and renovascular hypertension by reducing blood pressure, lowering plasma aldosterone, and increasing Total RNA was extracted from fresh rat tissues by TRIZOL natriuresis [10] . Our recent study indicated that aden-(Gibco BRL, Grand Island, NY, USA). The reaction mixture ovirus-mediated gene delivery of human ANP not only for RT contained 1 mg of total RNA from several tissues, 20 led to a prolonged blood pressure reduction but also pmol of the 3∞ primer (5∞-CACTGAGCACTTGTGGG-3∞ resulted in protection against salt-induced cardiac located at the second exon of the human ANP gene), 20 nmol hypertrophy and renal damage in hypertensive Dahl of dNTP, 0.2 mmol of DTT, 4 ml of 5×reverse transcription salt-sensitive rats [11] . in an adenovirus vector led to increased renal function CACCGTGAGCTTCCTCCTTT-3∞ from the first exon of and attenuation of renal lesions resulting from genta-the human ANP gene), 5 ml of 10×PCR buffer, and 0.5 U mycin administration. These findings suggest that ANP of Taq DNA polymerase were added to the RT mixture to gene therapy may have potential applications in treat-a total volume of 50 ml followed by 30 cycles of hot-start ing drug-induced nephrotoxicity.
PCR (94°C, 1 min; 55°C, 1 min; 72°C, 1 min) with Ampliwax (Perkin-Elmer Cetus Instruments, Norwalk, CT, USA) in a thermal cycler. Thirty ml of RT-PCR products were subjected
Subjects and methods
to a Southern blot analysis. A specific oligonucleotide (5∞-TAGGTCAGACCAGAGCT-3∞ from the first exon of the human ANP gene) was used as a probe for hybridization at
Preparation of replication-deficient adenovirus vector
42°C. The membrane was washed in 3×SSC twice at 42°C
Ad.RSV-ANP
and exposed to X-Omat film at −80°C ( Eastman Kodak Co., Rochester, NY, USA). Plasmid RSV-ANP was constructed as previous described [12] , in which the expression of human ANP cDNA was
Serum and urine collection
under the control of the Rous sarcoma virus long terminal repeat (RSV-LTR) and was followed by a SV40 poly A At various time points after injection of adenoviral vectors, signal sequence. The transcription unit of RSV-ANP-poly serum was collected and measured for blood urea nitrogen A, including the RSV-LTR, the human ANP cDNA, and a (BUN ) levels using a modified urease-indophenol method Simian virus 40 poly A signal sequence, was released from
[13]. Twenty-four-hour urine samples were collected on day the RSV-ANP plasmid by SalI digestion. Plasmid pAd.RSV-7 using metabolic cages. To eliminate food contamination in ANP was constructed by inserting the released fragment into urine samples, rats were only given drinking water during the adenovirus shuttle vector pAdLink.1 at a SalI site. The urine collection. Urine samples were collected and centrifuged pAd.RSV-ANP plasmid DNA was purified using a Qiagen at 1000 g to remove particles. The volume was measured and plasmid DNA kit (Qiagen, Chatsworth, CA, USA). The the supernatant was used for further analysis. purified DNA was sent to the Institute for Human Gene Therapy, Wistar Institute, Philadelphia to generate the adenovirus Ad.RSV-ANP harboring the RSV-ANP-poly A tran-Tissue preparation scription unit. Final production of Ad.RSV-ANP and Ad.RSV-LacZ harboring the LacZ gene was carried out in At 10 days after gene delivery, one rat from each group was this laboratory.
anesthetized intraperitoneally with pentobarbital at a dose of 50 mg/kg body weight and perfused with normal saline by cardiac puncture. Tissues were homogenized in normal
Animal treatment
saline with a Polytron (Brinkmann Instruments, Westbury, NY, USA). The homogenate was centrifuged at 600 g for Sprague-Dawley rats (male, 200-220 g body weight, Harlan 10 min. The supernatant was incubated in 0.5% sodium Sprague Dawley, Inc., Indianapolis, IN, USA) were used in deoxycholate and then centrifuged at 10 000 g for 30 min. this experiment. Rats were housed at a constant room Total protein in the supernatant was determined by Lowry's temperature with a 12 h light-dark cycle and had free access method [14] . to tap water and rat chow. The rats were divided at random into four groups. Three groups received gentamycin sulfate Radioimmunoassay (RIA) for human ANP (Sigma Chemical, St. Louis, MO, USA) subcutaneously at a dose of 80 mg/kg in saline solution (0.9% NaCl ). The
Immunoreactive human ANP levels were measured by direct injection was carried out for 10 consecutive days. The first RIA as previously described [12] . group was injected with adenovirus Ad.RSV-ANP (1.2×1010 plaque-forming units) and the second group with same number of adenovirus Ad.RSV-LacZ via the tail vein on the RIA for cGMP first day of gentamycin treatment. Third group received gentamycin alone. The control group was injected subcutane-Kidney tissues (100 mg) were homogenized in 1 ml 0.1 N HCl and the homogenate centrifuged at 12 000 g for 30 min. ously with saline. The animal experiments were conducted
The supernatant was diluted to 15100 and the procedure for assay of cGMP was conducted according to the general procedure as previously described [15] . Protein concentration was determined by Lowry's method [14] .
Measurement of urine flow rate, glomerular filtration rate and renal blood flow
Renal function was determined at 10 days after human ANP gene delivery. Glomerular filtration rate (GFR) and renal plasma flow (RPF ) were determined from the clearance of polyfructosan and para-aminohippuric acid, respectively [16 ] . Renal blood flow (RBF ) was calculated from RPF and haematocrit. Timed urine volume was determined gravimetrically.
Morphological and histological investigations
Rats were anaesthetized with pentobarbital (50 mg/kg, i.p.) and kidneys were removed, cleaned, washed in saline, blotted and weighed. Sections of the kidney were preserved in 4% phosphate-buffered formaldehyde solution and embedded in paraffin. Five mm-thick sections were cut and stained with haematoxylin and eosin (H&E) and/or periodic acid-Schiff (PAS) and analysed microscopically and morphometrically. Morphological changes were scored as follows ( Figure 1 ): (i) proximal tubule damage was found in parts of the outer cortex; (ii) proximal tubule damage was found throughout outer cortical nephrons; (iii) proximal tubule damage was found throughout outer and inner cortex; (iv) proximal tubule damage was found throughout the cortex and extended into the outer medulla. A score of zero (found only in controls) indicated no observable proximal tubule damage. Morphological evidence of proximal tubule damage included: swelling and disruption of cells, cell sloughing and tubular casts, and loss of PAS-positive apical brush border. All The results show that human ANP is expressed induced nephrotoxic rats in tissues relevant to cardiovascular and renal function Human ANP mRNA in gentamycin-induced nephro-following gene transfer in gentamycin-induced nephrotoxic rats after gene delivery was analysed by RT-PCR toxic rats. followed by Southern blot using specific oligonucleotide probes for human ANP. Total RNAs were pre-Immunoreactive human ANP levels after gene delivery pared from heart, aorta, kidney, and liver at 4 days after intravenous injection of adenoviral vectors The levels of human ANP in gentamycin-induced nephrotoxic rats were analysed by a RIA specific for Ad.RSV-ANP or Ad.RSV-LacZ. ANP mRNA was detected in the kidney, heart, aorta and liver ( Figure human ANP. Immunoreactive human ANP was detected in the heart (480.0±21.5 ng/mg protein) and 2, upper panel, left). The expression of ANP mRNA was not detected in control rats receiving adenoviral kidney (95.4±9.2 ng/mg protein) at 4 days after gene delivery. Human ANP was also detected in the kidney vector Ad.RSV-LacZ ( Figure 2, upper panel, right) . Figure 4 shows blood urea nitrogen (BUN ) levels in rats after gene delivery. BUN levels in the gentamycintreated group with or without Ad.RSV-LacZ gene delivery began to rise 7 days after gentamycin administration. At 10 days post-gene delivery there were two times higher levels of BUN in rats with gentamycin administration than the control group given saline Fig. 2 . Expression of human ANP mRNA in rats after ANP gene (47.3±0.3 and 44.7±0.8 vs 24.4±0.2 mg/100 ml delivery. The rats were sacrificed 4 days post-injection and 1 mg of serum, n=5, P<0.01). Although the BUN levels in RNA was used for RT-PCR and Southern blot analysis. Human rats injected with gentamycin and Ad.RSV-ANP ANP mRNA in rat tissues was amplified by a set of specific (37.6±0.9 mg/100 ml serum, n=5) was significantly oligonucleotides for human ANP which yielded a partial cDNA (500 bp) product as shown in the upper panel. b-Actin mRNA in higher than the control group given saline, it was rat tissues was amplified by a set of specific oligonucleotides which significantly lower than that of gentamycin-treated yielded a 500 bp product as shown in the lower panel. RNAs from group with or without Ad.RSV-LacZ groups liver, kidney, heart and aorta of rats receiving Ad.RSV-ANP of (P<0.01). The results indicate that ANP gene delivery Ad.RSV-LacZ are indicated in the figure. significantly attenuated BUN elevation in gentamycininduced nephrotoxicity in rats. (24.4±0.8 ng/mg protein, mean±SEM, n=4) at 10 days post gene delivery. Linear displacement curves Effects of ANP gene delivery on physiological for immunoreactive ANP in the heart and kidney of parameters in gentamycin-induced nephrotoxicity in rats gentamycin-induced nephrotoxic rats were parallel with the standard curve of human ANP, indicating Table 1 shows the results of physiological analysis of their immunological identity (Figure 3 ). Serial dilu-gentamycin-treated rats 7 days after gene delivery. tions of heart, liver and kidney extracts from control There were no significant differences in all parameters rats injected with Ad.RSV-LacZ showed a lack of between the control group and the gentamycin-treated parallelism with the human ANP standard curve. These groups with or without Ad.RSV-LacZ. However, results indicate that goat anti-human ANP antibody ANP gene delivery caused a significant increase has some cross-reactivity with rat ANP, however, in urine volume (16.1±1.3 vs 8.9±1.1 ml/day/100 g administration and gene delivery. Gentamycin was given subcutanelog-logit transformation of typical radioimmunoassay standard curve of human ANP and serial dilutions of heart and kidney samples ously, 80 mg/kg body weight daily, for 10 days. Adenovirus gene delivery was performed on the first day of gentamycin treatment. from rats receiving adenoviral vectors Ad.RSV-ANP. B/Bo is the percent of bound radioactivity in the presence and absence of Data are expressed as mean±SEM (n=5). *P<0.01 vs the gentamycin with and without Ad.RSV-LacZ groups; (#) control rats receivunlabaled human ANP using goat anti-human ANP antiserum. Human atrial natriuretic peptide standard curve is shown in the ing saline; ($) rats receiving gentamycin alone; (6) rats receiving gentamycin and Ad.RSV-LacZ; (+) rats receiving gentamycin and open circles (#), and serial dilutions of rat tissue extracts are shown as follows: heart ($) and kidney (6) .
Decreased blood urea nitrogen in rats receiving ANP gene delivery
Ad.RSV-ANP. Gentamycin-induced nephrotoxicity in rats receiving adenoviral vectors Ad.RSV-cHK or Ad.RSV-LacZ via the tail vein on the first day of gentamycin administration. Urine collection was performed 7 days after gene delivery. Values for each group are reported as mean±SEM (n=8). Statistical significance among the four groups were determined by ANOVA. aP<0.05 vs gentamycin and Ad.RSV-LacZ group. body weight, n=8, P<0.01) and water intake Effects of ANP gene delivery on renal cGMP (17.5±2.1 vs 5.6±1.0 ml/day/100 g body weight, n= Figure 5 shows renal cGMP levels measured 10 days 8, P<0.01) compared to control rats receiving after gene delivery. Cyclic GMP levels were significAd.RSV-LacZ. Urinary sodium and potassium excre-antly lower in gentamycin-treated groups with or withtion in the group receiving ANP gene delivery was also out Ad.RSV-LacZ than the control group received significantly higher than that of other groups. Table 2 shows the results of renal hemodynamics in gentamycin-induced nephrotoxic rats 10 days after gene delivery. ANP gene delivery caused a significant increase in urine flow (11.1±0.3 ml/min/g kidney weight, n=4, P<0.01) as compared to the Ad.RSVLacZ gene delivery group (5.0±0.2 ml/min/g kidney weight, n=4), the gentamycin-treated group (4.4± 0.3 ml/min/g kidney weight, n=4), and the salineinjected control rats (5.7±0.4 ml/min/g kidney weight, n=4). Similarly, rats injected with Ad.RSV-ANP induced significant increase in GFR (1.83±0.05 vs 0.83±0.04 ml/min/g kidney weight, n=4, P<0.01) and RBF (18.9±0.9 vs 9.2±0.6 ml/min/g kidney Fig. 5 . Effects of human ANP gene delivery on renal cGMP levels. weight, n=4, P<0.01) when compared with rats Data are expressed as mean±SEM (n=4). *P<0.01 vs rats receiving gentamycin alone or with Ad.RSV-LacZ.
Effects of ANP gene delivery on the renal function in gentamycin nephrotoxic rats
receiving the control adenovirus Ad.RSV-LacZ. Gentamycin-induced nephrotoxicity in rats receiving adenoviral vectors Ad.RSV-ANP or Ad.RSV-LacZ via the tail vein on the first day of gentamycin administration. Renal function studies were performed 10 days after gene delivery. UF, urine flow; GFR, glomerular filtration rate; RBF, renal blood flow; KW, kidney weight. Values for each group are reported as mean±SEM (n=4). Statistical significance among the four groups were determined by ANOVA. aP<0.01 vs gentamycin and Ad.RSV-LacZ group.
saline (1.3±0.1 and 1.3±0.1 vs 2.8±0.1 pmol/mg ANP), swelling of proximal tubular cells was seen, but fewer dilated renal tubules were present and frank protein, n=4, P<0.01). However, a significant cellular necrosis was rare ( Figure 6D ). increase of cGMP in the kidney was observed in the Figure 7 shows the morphology of kidney stained Ad.RSV-ANP group (4.0±0.1 pmol/mg protein, n= by PAS for carbohydrates in brush borders and base-4, P<0.01) compared to the control Ad.RSV-LacZ ment membranes. The morphology of the kidney in group or control with saline.
control rats ( Figure 7A ) without gentamycin treatment was well preserved in both the cortex and medulla.
Effects of ANP gene delivery on kidney morphology
Proximal tubule brush border throughout cortex and Figure 6 shows the morphology of kidney stained with outer medulla stained prominently with PAS, as did H&E and examined by light-microscopy. The fixation, basement membrane in renal gromeruli and proximal embedding and staining of non-treated control animals tubules. In the renal cortex of rats injected with genta-( Figure 6A ) resulted in well preserved kidney morpho-mycin alone or gentamycin and Ad.RSV-LacZ, there logy in both the cortex and medulla. A widespread were dilated proximal tubules generally lacking of tubular dilation and damage were observed in the renal brush border. Lumenal casts were generally PAScortex of gentamycin-treated rats either alone or fol-positive, most probably derived from sloughed brush lowed by Ad.RSV-LacZ ( Figure 6B and C ) . Most border glycoprotein and reabsorption droplets from proximal tubules were damaged and many were either damaged proximal tubule cells ( Figure 7B and C ) . dilated or filled with necrotic cells. Distal tubules The ANP gene-treated group ( Figure 7D ) exhibited exhibited less damage and collecting ducts appeared less damage than either gentamycin alone or gentamyrelatively normal. Cortical renal tubular lumens were cin with Ad.RSV-LacZ group. Although some tubular often filled with protein casts. Medullary tubules did damage persisted, evidence of preservation and regennot appear damaged in structure, but protein casts eration of proximal tubules included: intense PAS often filled the lumens, particularly in the outer staining of the apical brush border in many tubules and fewer protein casts thoughout the kidneys. medulla. In the ANP gene-treated group (Ad.RSV- The quantitative evaluation of renal n=8) and there were no differences between these two groups. Although the rats receiving gentamycin and tubular damage was scored as described in Figure 1 . Gentamycin-treated animals with or without Ad.RSV-Ad.RSV-ANP had some tubular damage (Score; 1.3±0.1, n=8), the damage was significantly less than in two control groups (P<0.01). The results indicate that ANP gene delivery significantly attenuated tubular damage induced by gentamycin.
Discussion
In this study, we have shown that adenovirus-mediated delivery of the human ANP gene via intravenous injection displayed protective effects on gentamycininduced nephrotoxicity in rats. Histologically, proximal tubular damage was diminished. ANP gene delivery significantly attenuated the elevation of BUN levels. In addition, ANP gene delivery also enhanced renal findings suggest a potential application of ANP gene
